Novigenix, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer. The study titled, “Multimodal Integration of Blood RNA and ctDNA Reflects Response to Immunotherapy in Metastatic Urothelial Cancer” [link], has been published in JCI Insight.
Metastatic urothelial cancer is a highly aggressive disease with a poor prognosis, with approximately 30% of patients responding to immune checkpoint inhibitors. This underscores the urgent need for reliable biomarkers to guide treatment strategies. Novigenix’s AI-powered LITOSeek™ platform addresses this need by integrating RNA-based immune profiling with circulating tumor DNA (ctDNA) analysis, providing comprehensive assessment of the disease. This novel approach offers biopharma partners differentiated solutions for predictive biomarker discovery, therapy development, and clinical trial optimization.
